Cleveland Clinic, Cleveland, Ohio 44195, USA.
Emerg Infect Dis. 2013 Jul;19(7):1074-83. doi: 10.3201/eid1907.121830.
Serotyping data for pneumococci causing invasive and noninvasive disease in 2008-2009 and 2010-2011 from >43 US centers were compared with data from preconjugate vaccine (1999-2000) and postconjugate vaccine (2004-2005) periods. Prevalence of 7-valent pneumococcal conjugate vaccine serotypes decreased from 64% of invasive and 50% of noninvasive isolates in 1999-2000 to 3.8% and 4.2%, respectively, in 2010-2011. Increases in serotype 19A stopped after introduction of 13-valent pneumococcal vaccine (PCV13) in 2010. Prevalences of other predominant serotypes included in or related to PCV13 (3, 6C, 7F) also remained similar for 2008-2009 and 2010-2011. The only major serotype that increased from 2008-2009 to 2010-2011 was nonvaccine serotype 35B. These data show that introduction of the 7-valent vaccine has dramatically decreased prevalence of its serotypes and that addition of serotypes in PCV13 could provide coverage of 39% of isolates that continue to cause disease.
2008-2009 年和 2010-2011 年期间，来自 43 个以上美国中心的引起侵袭性和非侵袭性疾病的肺炎球菌的血清型数据与预共轭疫苗（1999-2000 年）和后共轭疫苗（2004-2005 年）的数据进行了比较。1999-2000 年 7 价肺炎球菌结合疫苗血清型的侵袭性和非侵袭性分离株的流行率分别从 64%和 50%降至 2010-2011 年的 3.8%和 4.2%。2010 年 13 价肺炎球菌疫苗（PCV13）上市后，血清型 19A 的流行率增加停止。包括在 PCV13 中的或与之相关的其他主要血清型（3、6C、7F）的流行率在 2008-2009 年和 2010-2011 年也保持相似。唯一从 2008-2009 年到 2010-2011 年增加的主要血清型是非疫苗血清型 35B。这些数据表明，7 价疫苗的引入大大降低了其血清型的流行率，而 PCV13 中添加的血清型可能为继续引起疾病的 39%的分离株提供覆盖。
